Skip to main navigation Skip to search Skip to main content

Sphingomyelin liposomes containing porphyrin-phospholipid for irinotecan chemophototherapy

  • Kevin A. Carter
  • , Dandan Luo
  • , Aida Razi
  • , Jumin Geng
  • , Shuai Shao
  • , Joaquin Ortega
  • , Jonathan F. Lovell
  • SUNY Buffalo
  • McMaster University

Research output: Contribution to journalArticlepeer-review

62 Scopus citations

Abstract

Porphyrin-phospholipid (PoP) liposomes can entrap anti-cancer agents and release them in response to near infrared (NIR) light. Doxorubicin, when remotely loaded via an ammonium sulfate gradient at a high drug-to-lipid ratio, formed elongated crystals that altered liposome morphology and could not be loaded into liposomes with higher PoP content. On the other hand, irinotecan could also be remotely loaded but did not form large crystals and did not induce liposome elongation. The loading, stability, and NIR light-triggered release of irinotecan in PoP liposomes was altered by the types of lipids used and the presence of PEGylation. Sphingomyelin, which has been explored previously for liposomal irinotecan, was found to produce liposomes with relatively improved serum stability and rapid NIR light-triggered drug release. PoP liposomes composed from sphingomyelin, cholesterol and 2 molar percent PoP rapidly released irinotecan in vivo in response to NIR irradiation as monitored by intravital microscopy and also induced effective tumor eradication in mice bearing MIA Paca-2 subcutaneous tumor xenografts.

Original languageEnglish
Pages (from-to)2329-2336
Number of pages8
JournalTheranostics
Volume6
Issue number13
DOIs
StatePublished - 2016

Keywords

  • Chemophototherapy
  • Irinotecan
  • Liposomes

Fingerprint

Dive into the research topics of 'Sphingomyelin liposomes containing porphyrin-phospholipid for irinotecan chemophototherapy'. Together they form a unique fingerprint.

Cite this